Industry Research Reports

Home > Reports > Pharma & Healthcare > Global Mitochondrial-based Therapeutics Market Research Report 2023

Global Mitochondrial-based Therapeutics Market Research Report 2023

Industry: Pharma & Healthcare

Published: 2023-08-07

Pages: 87 Pages

Report ld: 1503610

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

Mitochondria are therefore vital for normal cellular function, including intracellular metabolic activities and signal transduction of various cellular pathways. They are involved in cellular ion homeostasis, oxidative stress, and apoptotic and necrotic cell death.

According to QYResearch’s new survey, global Mitochondrial-based Therapeutics market is projected to reach US$ 651.3 million in 2029, increasing from US$ 379 million in 2022, with the CAGR of 7.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Mitochondrial-based Therapeutics market research.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Mitochondrial-based Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company
    Reneo Pharmaceutical
    Pfizer Inc.
    Norvartis AG
    Takeda Pharmaceuticals
    Amgen Inc.
    NeuroVive Pharmaceutical AB
    Entogene AG
    Stealth Biotherapeutics
    Ixchel Pharma
    Reata Pharmaceuticals

Segment by Type
    Oral
    Intravenous

Segment by Application
    Mitochondrial Myopathy
    Leber’s heredity Optic Neuropathy
    Leigh Syndrome
    Mitochondrial DNA Depletion Syndrome
    Other

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        Rest of Asia
    Latin America
        Mexico
        Brazil
        Rest of Latin America
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE
        Rest of MEA

The Mitochondrial-based Therapeutics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source

Table of Contents

 1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Mitochondrial-based Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
        1.2.2 Oral
        1.2.3 Intravenous
    1.3 Market by Application
        1.3.1 Global Mitochondrial-based Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029
        1.3.2 Mitochondrial Myopathy
        1.3.3 Leber’s heredity Optic Neuropathy
        1.3.4 Leigh Syndrome
        1.3.5 Mitochondrial DNA Depletion Syndrome
        1.3.6 Other
    1.4 Study Objectives
    1.5 Years Considered
    1.6 Years Considered

 2 Global Growth Trends
    2.1 Global Mitochondrial-based Therapeutics Market Perspective (2018-2029)
    2.2 Mitochondrial-based Therapeutics Growth Trends by Region
        2.2.1 Global Mitochondrial-based Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
        2.2.2 Mitochondrial-based Therapeutics Historic Market Size by Region (2018-2023)
        2.2.3 Mitochondrial-based Therapeutics Forecasted Market Size by Region (2024-2029)
    2.3 Mitochondrial-based Therapeutics Market Dynamics
        2.3.1 Mitochondrial-based Therapeutics Industry Trends
        2.3.2 Mitochondrial-based Therapeutics Market Drivers
        2.3.3 Mitochondrial-based Therapeutics Market Challenges
        2.3.4 Mitochondrial-based Therapeutics Market Restraints

 3 Competition Landscape by Key Players
    3.1 Global Top Mitochondrial-based Therapeutics Players by Revenue
        3.1.1 Global Top Mitochondrial-based Therapeutics Players by Revenue (2018-2023)
        3.1.2 Global Mitochondrial-based Therapeutics Revenue Market Share by Players (2018-2023)
    3.2 Global Mitochondrial-based Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Mitochondrial-based Therapeutics Revenue
    3.4 Global Mitochondrial-based Therapeutics Market Concentration Ratio
        3.4.1 Global Mitochondrial-based Therapeutics Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Mitochondrial-based Therapeutics Revenue in 2022
    3.5 Mitochondrial-based Therapeutics Key Players Head office and Area Served
    3.6 Key Players Mitochondrial-based Therapeutics Product Solution and Service
    3.7 Date of Enter into Mitochondrial-based Therapeutics Market
    3.8 Mergers & Acquisitions, Expansion Plans

 4 Mitochondrial-based Therapeutics Breakdown Data by Type
    4.1 Global Mitochondrial-based Therapeutics Historic Market Size by Type (2018-2023)
    4.2 Global Mitochondrial-based Therapeutics Forecasted Market Size by Type (2024-2029)

 5 Mitochondrial-based Therapeutics Breakdown Data by Application
    5.1 Global Mitochondrial-based Therapeutics Historic Market Size by Application (2018-2023)
    5.2 Global Mitochondrial-based Therapeutics Forecasted Market Size by Application (2024-2029)

 6 North America
    6.1 North America Mitochondrial-based Therapeutics Market Size (2018-2029)
    6.2 North America Mitochondrial-based Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
    6.3 North America Mitochondrial-based Therapeutics Market Size by Country (2018-2023)
    6.4 North America Mitochondrial-based Therapeutics Market Size by Country (2024-2029)
    6.5 United States
    6.6 Canada

 7 Europe
    7.1 Europe Mitochondrial-based Therapeutics Market Size (2018-2029)
    7.2 Europe Mitochondrial-based Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
    7.3 Europe Mitochondrial-based Therapeutics Market Size by Country (2018-2023)
    7.4 Europe Mitochondrial-based Therapeutics Market Size by Country (2024-2029)
    7.5 Germany
    7.6 France
    7.7 U.K.
    7.8 Italy
    7.9 Russia
    7.10 Nordic Countries

 8 Asia-Pacific
    8.1 Asia-Pacific Mitochondrial-based Therapeutics Market Size (2018-2029)
    8.2 Asia-Pacific Mitochondrial-based Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029
    8.3 Asia-Pacific Mitochondrial-based Therapeutics Market Size by Region (2018-2023)
    8.4 Asia-Pacific Mitochondrial-based Therapeutics Market Size by Region (2024-2029)
    8.5 China
    8.6 Japan
    8.7 South Korea
    8.8 Southeast Asia
    8.9 India
    8.10 Australia

 9 Latin America
    9.1 Latin America Mitochondrial-based Therapeutics Market Size (2018-2029)
    9.2 Latin America Mitochondrial-based Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
    9.3 Latin America Mitochondrial-based Therapeutics Market Size by Country (2018-2023)
    9.4 Latin America Mitochondrial-based Therapeutics Market Size by Country (2024-2029)
    9.5 Mexico
    9.6 Brazil

 10 Middle East & Africa
    10.1 Middle East & Africa Mitochondrial-based Therapeutics Market Size (2018-2029)
    10.2 Middle East & Africa Mitochondrial-based Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
    10.3 Middle East & Africa Mitochondrial-based Therapeutics Market Size by Country (2018-2023)
    10.4 Middle East & Africa Mitochondrial-based Therapeutics Market Size by Country (2024-2029)
    10.5 Turkey
    10.6 Saudi Arabia
    10.7 UAE

 11 Key Players Profiles
    11.1 Reneo Pharmaceutical
        11.1.1 Reneo Pharmaceutical Company Detail
        11.1.2 Reneo Pharmaceutical Business Overview
        11.1.3 Reneo Pharmaceutical Mitochondrial-based Therapeutics Introduction
        11.1.4 Reneo Pharmaceutical Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
        11.1.5 Reneo Pharmaceutical Recent Development
    11.2 Pfizer Inc.
        11.2.1 Pfizer Inc. Company Detail
        11.2.2 Pfizer Inc. Business Overview
        11.2.3 Pfizer Inc. Mitochondrial-based Therapeutics Introduction
        11.2.4 Pfizer Inc. Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
        11.2.5 Pfizer Inc. Recent Development
    11.3 Norvartis AG
        11.3.1 Norvartis AG Company Detail
        11.3.2 Norvartis AG Business Overview
        11.3.3 Norvartis AG Mitochondrial-based Therapeutics Introduction
        11.3.4 Norvartis AG Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
        11.3.5 Norvartis AG Recent Development
    11.4 Takeda Pharmaceuticals
        11.4.1 Takeda Pharmaceuticals Company Detail
        11.4.2 Takeda Pharmaceuticals Business Overview
        11.4.3 Takeda Pharmaceuticals Mitochondrial-based Therapeutics Introduction
        11.4.4 Takeda Pharmaceuticals Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
        11.4.5 Takeda Pharmaceuticals Recent Development
    11.5 Amgen Inc.
        11.5.1 Amgen Inc. Company Detail
        11.5.2 Amgen Inc. Business Overview
        11.5.3 Amgen Inc. Mitochondrial-based Therapeutics Introduction
        11.5.4 Amgen Inc. Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
        11.5.5 Amgen Inc. Recent Development
    11.6 NeuroVive Pharmaceutical AB
        11.6.1 NeuroVive Pharmaceutical AB Company Detail
        11.6.2 NeuroVive Pharmaceutical AB Business Overview
        11.6.3 NeuroVive Pharmaceutical AB Mitochondrial-based Therapeutics Introduction
        11.6.4 NeuroVive Pharmaceutical AB Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
        11.6.5 NeuroVive Pharmaceutical AB Recent Development
    11.7 Entogene AG
        11.7.1 Entogene AG Company Detail
        11.7.2 Entogene AG Business Overview
        11.7.3 Entogene AG Mitochondrial-based Therapeutics Introduction
        11.7.4 Entogene AG Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
        11.7.5 Entogene AG Recent Development
    11.8 Stealth Biotherapeutics
        11.8.1 Stealth Biotherapeutics Company Detail
        11.8.2 Stealth Biotherapeutics Business Overview
        11.8.3 Stealth Biotherapeutics Mitochondrial-based Therapeutics Introduction
        11.8.4 Stealth Biotherapeutics Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
        11.8.5 Stealth Biotherapeutics Recent Development
    11.9 Ixchel Pharma
        11.9.1 Ixchel Pharma Company Detail
        11.9.2 Ixchel Pharma Business Overview
        11.9.3 Ixchel Pharma Mitochondrial-based Therapeutics Introduction
        11.9.4 Ixchel Pharma Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
        11.9.5 Ixchel Pharma Recent Development
    11.10 Reata Pharmaceuticals
        11.10.1 Reata Pharmaceuticals Company Detail
        11.10.2 Reata Pharmaceuticals Business Overview
        11.10.3 Reata Pharmaceuticals Mitochondrial-based Therapeutics Introduction
        11.10.4 Reata Pharmaceuticals Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
        11.10.5 Reata Pharmaceuticals Recent Development

 12 Analyst's Viewpoints/Conclusions

 13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

Table of Figures

List of Tables
    Table 1. Global Mitochondrial-based Therapeutics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
    Table 2. Key Players of Oral
    Table 3. Key Players of Intravenous
    Table 4. Global Mitochondrial-based Therapeutics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
    Table 5. Global Mitochondrial-based Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 6. Global Mitochondrial-based Therapeutics Market Size by Region (2018-2023) & (US$ Million)
    Table 7. Global Mitochondrial-based Therapeutics Market Share by Region (2018-2023)
    Table 8. Global Mitochondrial-based Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 9. Global Mitochondrial-based Therapeutics Market Share by Region (2024-2029)
    Table 10. Mitochondrial-based Therapeutics Market Trends
    Table 11. Mitochondrial-based Therapeutics Market Drivers
    Table 12. Mitochondrial-based Therapeutics Market Challenges
    Table 13. Mitochondrial-based Therapeutics Market Restraints
    Table 14. Global Mitochondrial-based Therapeutics Revenue by Players (2018-2023) & (US$ Million)
    Table 15. Global Mitochondrial-based Therapeutics Market Share by Players (2018-2023)
    Table 16. Global Top Mitochondrial-based Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mitochondrial-based Therapeutics as of 2022)
    Table 17. Ranking of Global Top Mitochondrial-based Therapeutics Companies by Revenue (US$ Million) in 2022
    Table 18. Global 5 Largest Players Market Share by Mitochondrial-based Therapeutics Revenue (CR5 and HHI) & (2018-2023)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players Mitochondrial-based Therapeutics Product Solution and Service
    Table 21. Date of Enter into Mitochondrial-based Therapeutics Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Mitochondrial-based Therapeutics Market Size by Type (2018-2023) & (US$ Million)
    Table 24. Global Mitochondrial-based Therapeutics Revenue Market Share by Type (2018-2023)
    Table 25. Global Mitochondrial-based Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 26. Global Mitochondrial-based Therapeutics Revenue Market Share by Type (2024-2029)
    Table 27. Global Mitochondrial-based Therapeutics Market Size by Application (2018-2023) & (US$ Million)
    Table 28. Global Mitochondrial-based Therapeutics Revenue Market Share by Application (2018-2023)
    Table 29. Global Mitochondrial-based Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 30. Global Mitochondrial-based Therapeutics Revenue Market Share by Application (2024-2029)
    Table 31. North America Mitochondrial-based Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 32. North America Mitochondrial-based Therapeutics Market Size by Country (2018-2023) & (US$ Million)
    Table 33. North America Mitochondrial-based Therapeutics Market Size by Country (2024-2029) & (US$ Million)
    Table 34. Europe Mitochondrial-based Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 35. Europe Mitochondrial-based Therapeutics Market Size by Country (2018-2023) & (US$ Million)
    Table 36. Europe Mitochondrial-based Therapeutics Market Size by Country (2024-2029) & (US$ Million)
    Table 37. Asia-Pacific Mitochondrial-based Therapeutics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 38. Asia-Pacific Mitochondrial-based Therapeutics Market Size by Region (2018-2023) & (US$ Million)
    Table 39. Asia-Pacific Mitochondrial-based Therapeutics Market Size by Region (2024-2029) & (US$ Million)
    Table 40. Latin America Mitochondrial-based Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 41. Latin America Mitochondrial-based Therapeutics Market Size by Country (2018-2023) & (US$ Million)
    Table 42. Latin America Mitochondrial-based Therapeutics Market Size by Country (2024-2029) & (US$ Million)
    Table 43. Middle East & Africa Mitochondrial-based Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 44. Middle East & Africa Mitochondrial-based Therapeutics Market Size by Country (2018-2023) & (US$ Million)
    Table 45. Middle East & Africa Mitochondrial-based Therapeutics Market Size by Country (2024-2029) & (US$ Million)
    Table 46. Reneo Pharmaceutical Company Detail
    Table 47. Reneo Pharmaceutical Business Overview
    Table 48. Reneo Pharmaceutical Mitochondrial-based Therapeutics Product
    Table 49. Reneo Pharmaceutical Revenue in Mitochondrial-based Therapeutics Business (2018-2023) & (US$ Million)
    Table 50. Reneo Pharmaceutical Recent Development
    Table 51. Pfizer Inc. Company Detail
    Table 52. Pfizer Inc. Business Overview
    Table 53. Pfizer Inc. Mitochondrial-based Therapeutics Product
    Table 54. Pfizer Inc. Revenue in Mitochondrial-based Therapeutics Business (2018-2023) & (US$ Million)
    Table 55. Pfizer Inc. Recent Development
    Table 56. Norvartis AG Company Detail
    Table 57. Norvartis AG Business Overview
    Table 58. Norvartis AG Mitochondrial-based Therapeutics Product
    Table 59. Norvartis AG Revenue in Mitochondrial-based Therapeutics Business (2018-2023) & (US$ Million)
    Table 60. Norvartis AG Recent Development
    Table 61. Takeda Pharmaceuticals Company Detail
    Table 62. Takeda Pharmaceuticals Business Overview
    Table 63. Takeda Pharmaceuticals Mitochondrial-based Therapeutics Product
    Table 64. Takeda Pharmaceuticals Revenue in Mitochondrial-based Therapeutics Business (2018-2023) & (US$ Million)
    Table 65. Takeda Pharmaceuticals Recent Development
    Table 66. Amgen Inc. Company Detail
    Table 67. Amgen Inc. Business Overview
    Table 68. Amgen Inc. Mitochondrial-based Therapeutics Product
    Table 69. Amgen Inc. Revenue in Mitochondrial-based Therapeutics Business (2018-2023) & (US$ Million)
    Table 70. Amgen Inc. Recent Development
    Table 71. NeuroVive Pharmaceutical AB Company Detail
    Table 72. NeuroVive Pharmaceutical AB Business Overview
    Table 73. NeuroVive Pharmaceutical AB Mitochondrial-based Therapeutics Product
    Table 74. NeuroVive Pharmaceutical AB Revenue in Mitochondrial-based Therapeutics Business (2018-2023) & (US$ Million)
    Table 75. NeuroVive Pharmaceutical AB Recent Development
    Table 76. Entogene AG Company Detail
    Table 77. Entogene AG Business Overview
    Table 78. Entogene AG Mitochondrial-based Therapeutics Product
    Table 79. Entogene AG Revenue in Mitochondrial-based Therapeutics Business (2018-2023) & (US$ Million)
    Table 80. Entogene AG Recent Development
    Table 81. Stealth Biotherapeutics Company Detail
    Table 82. Stealth Biotherapeutics Business Overview
    Table 83. Stealth Biotherapeutics Mitochondrial-based Therapeutics Product
    Table 84. Stealth Biotherapeutics Revenue in Mitochondrial-based Therapeutics Business (2018-2023) & (US$ Million)
    Table 85. Stealth Biotherapeutics Recent Development
    Table 86. Ixchel Pharma Company Detail
    Table 87. Ixchel Pharma Business Overview
    Table 88. Ixchel Pharma Mitochondrial-based Therapeutics Product
    Table 89. Ixchel Pharma Revenue in Mitochondrial-based Therapeutics Business (2018-2023) & (US$ Million)
    Table 90. Ixchel Pharma Recent Development
    Table 91. Reata Pharmaceuticals Company Detail
    Table 92. Reata Pharmaceuticals Business Overview
    Table 93. Reata Pharmaceuticals Mitochondrial-based Therapeutics Product
    Table 94. Reata Pharmaceuticals Revenue in Mitochondrial-based Therapeutics Business (2018-2023) & (US$ Million)
    Table 95. Reata Pharmaceuticals Recent Development
    Table 96. Research Programs/Design for This Report
    Table 97. Key Data Information from Secondary Sources
    Table 98. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Mitochondrial-based Therapeutics Market Size Comparison by Type (2023-2029) & (US$ Million)
    Figure 2. Global Mitochondrial-based Therapeutics Market Share by Type: 2022 VS 2029
    Figure 3. Oral Features
    Figure 4. Intravenous Features
    Figure 5. Global Mitochondrial-based Therapeutics Market Size Comparison by Application (2023-2029) & (US$ Million)
    Figure 6. Global Mitochondrial-based Therapeutics Market Share by Application: 2022 VS 2029
    Figure 7. Mitochondrial Myopathy Case Studies
    Figure 8. Leber’s heredity Optic Neuropathy Case Studies
    Figure 9. Leigh Syndrome Case Studies
    Figure 10. Mitochondrial DNA Depletion Syndrome Case Studies
    Figure 11. Other Case Studies
    Figure 12. Mitochondrial-based Therapeutics Report Years Considered
    Figure 13. Global Mitochondrial-based Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2029
    Figure 14. Global Mitochondrial-based Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2029
    Figure 15. Global Mitochondrial-based Therapeutics Market Share by Region: 2022 VS 2029
    Figure 16. Global Mitochondrial-based Therapeutics Market Share by Players in 2022
    Figure 17. Global Top Mitochondrial-based Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mitochondrial-based Therapeutics as of 2022)
    Figure 18. The Top 10 and 5 Players Market Share by Mitochondrial-based Therapeutics Revenue in 2022
    Figure 19. North America Mitochondrial-based Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 20. North America Mitochondrial-based Therapeutics Market Share by Country (2018-2029)
    Figure 21. United States Mitochondrial-based Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 22. Canada Mitochondrial-based Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 23. Europe Mitochondrial-based Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 24. Europe Mitochondrial-based Therapeutics Market Share by Country (2018-2029)
    Figure 25. Germany Mitochondrial-based Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 26. France Mitochondrial-based Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 27. U.K. Mitochondrial-based Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 28. Italy Mitochondrial-based Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 29. Russia Mitochondrial-based Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 30. Nordic Countries Mitochondrial-based Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 31. Asia-Pacific Mitochondrial-based Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 32. Asia-Pacific Mitochondrial-based Therapeutics Market Share by Region (2018-2029)
    Figure 33. China Mitochondrial-based Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 34. Japan Mitochondrial-based Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 35. South Korea Mitochondrial-based Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 36. Southeast Asia Mitochondrial-based Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 37. India Mitochondrial-based Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 38. Australia Mitochondrial-based Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 39. Latin America Mitochondrial-based Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 40. Latin America Mitochondrial-based Therapeutics Market Share by Country (2018-2029)
    Figure 41. Mexico Mitochondrial-based Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 42. Brazil Mitochondrial-based Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 43. Middle East & Africa Mitochondrial-based Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 44. Middle East & Africa Mitochondrial-based Therapeutics Market Share by Country (2018-2029)
    Figure 45. Turkey Mitochondrial-based Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 46. Saudi Arabia Mitochondrial-based Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 47. Reneo Pharmaceutical Revenue Growth Rate in Mitochondrial-based Therapeutics Business (2018-2023)
    Figure 48. Pfizer Inc. Revenue Growth Rate in Mitochondrial-based Therapeutics Business (2018-2023)
    Figure 49. Norvartis AG Revenue Growth Rate in Mitochondrial-based Therapeutics Business (2018-2023)
    Figure 50. Takeda Pharmaceuticals Revenue Growth Rate in Mitochondrial-based Therapeutics Business (2018-2023)
    Figure 51. Amgen Inc. Revenue Growth Rate in Mitochondrial-based Therapeutics Business (2018-2023)
    Figure 52. NeuroVive Pharmaceutical AB Revenue Growth Rate in Mitochondrial-based Therapeutics Business (2018-2023)
    Figure 53. Entogene AG Revenue Growth Rate in Mitochondrial-based Therapeutics Business (2018-2023)
    Figure 54. Stealth Biotherapeutics Revenue Growth Rate in Mitochondrial-based Therapeutics Business (2018-2023)
    Figure 55. Ixchel Pharma Revenue Growth Rate in Mitochondrial-based Therapeutics Business (2018-2023)
    Figure 56. Reata Pharmaceuticals Revenue Growth Rate in Mitochondrial-based Therapeutics Business (2018-2023)
    Figure 57. Bottom-up and Top-down Approaches for This Report
    Figure 58. Data Triangulation
    Figure 59. Key Executives Interviewed

Description

Mitochondria are therefore vital for normal cellular function, including intracellular metabolic activities and signal transduction of various cellular pathways. They are involved in cellular ion homeostasis, oxidative stress, and apoptotic and necrotic cell death.

According to QYResearch’s new survey, global Mitochondrial-based Therapeutics market is projected to reach US$ 651.3 million in 2029, increasing from US$ 379 million in 2022, with the CAGR of 7.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Mitochondrial-based Therapeutics market research.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Mitochondrial-based Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company
    Reneo Pharmaceutical
    Pfizer Inc.
    Norvartis AG
    Takeda Pharmaceuticals
    Amgen Inc.
    NeuroVive Pharmaceutical AB
    Entogene AG
    Stealth Biotherapeutics
    Ixchel Pharma
    Reata Pharmaceuticals

Segment by Type
    Oral
    Intravenous

Segment by Application
    Mitochondrial Myopathy
    Leber’s heredity Optic Neuropathy
    Leigh Syndrome
    Mitochondrial DNA Depletion Syndrome
    Other

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        Rest of Asia
    Latin America
        Mexico
        Brazil
        Rest of Latin America
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE
        Rest of MEA

The Mitochondrial-based Therapeutics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source

Industry: Pharma & Healthcare

Published: 2023-08-07

Pages: 87 Pages

Report ld: 1503610

Request Sample

Pre-Order Enquiry

CHOOSE LICENSE TYPE

Single User License

USD 2900.00

Multi Users License

USD 4350.00

Corporate Users License